Barry Ticho sold $127k of STOK
CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc.. 10,000 shares at an average of $12.68, traded Nov 1, 2024, filed Nov 5, 2024.
Score components
- +15RoleOfficer
- +11Trade size$127k at market
- +20Share of holdings soldSold 80% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.7%, 3m -3.4%, 6m -33.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026135, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | MOption exercise Common Stock10b5-1 | +10,000 | $0.60 | $6,000 | 12,485 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.68 | $127k | 2,485 | Nov 5, 2024 |
| Nov 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 10,000 | Nov 5, 2024 |
Related signals
Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $17k 627 shares | -3% | |
| 8Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $27k 1,051 shares | -5% | |
| 11Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $170k 5,545 shares | -22% | |
| 32Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $445k 22,117 shares | -89% | |
| 45Moderate | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $1.2M 61,885 shares | -40% | |
| 25Weak | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $109k 5,501 shares | -23% | |
| 35Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $31k 1,683 shares | -7% | |
| 42Moderate | Stoke Therapeutics, Inc. | Edward M. Kaye MD CEO | $221k 12,126 shares | -7% | |
| 42Moderate | Stoke Therapeutics, Inc. | Barry Ticho CHIEF MEDICAL OFFICER | $51k 2,805 shares | -10% | |
| 32Weak | Stoke Therapeutics, Inc. | Jonathan Allan GENERAL COUNSEL & CORP SEC | $206k 13,712 shares | -41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.